As shortages of personal protective equipment persist during the coronavirus pandemic, 3D printing has helped to alleviate some of the gaps. But Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine, and his team are using the process in a more innovative way: creating tiny replicas of human organs — some as small as a pinhead — to test drugs to fight COVID-19.
The team is constructing miniature lungs and colons — two organs particularly affected by the coronavirus — then sending them overnight by courier for testing at a biosafety lab at George Mason University in Fairfax, Virginia. While they initially created some of the organoids by hand using a pipette, they are beginning to print these at scale for research as the pandemic continues to surge.
In the last few years, Atala’s institute had already printed these tiny clusters of cells to test drug efficacy against bacteria and infectious diseases like the Zika virus, “but we never thought we’d be considering this for a pandemic,” he said. His team has the ability to print “thousands an hour,” he said from his lab in Winston-Salem, North Carolina.
The process of constructing human tissue this way is a form of bioprinting. While its use in humans is still years away, researchers are honing the methods to test drugs and, eventually, to create skin and full-size organs for transplanting. Researchers are making strides in printing skin, critical for burn victims; managing diseases like diabetes in which wound healing is difficult; and for the testing of cosmetics without harming animals, or, of course, humans.
“Even to us it sometimes seems like science fiction,” said Akhilesh Gaharwar, who directs a cross-disciplinary lab in the biomedical engineering department at Texas A&M University that focuses on bioprinting and other approaches to regenerative medicine.
Bioprinting’s importance for pharmaceutical analysis is paramount now, not only for potential COVID-19 treatments but also for testing treatments for cancer and other diseases. Atala says that the organoids allow researchers to analyze a drug’s effect on an organ “without the noise” of an individual’s metabolism.
He cited Rezulin, a popular diabetes drug recalled in 2000 after there was evidence of liver failure. His lab tested an archived version of the drug, and Atala said that within two weeks, the liver toxicity became apparent. What accounts for the difference? An organoid replicates an organ in its purest form and offers data points that might not occur in clinical trials, he said, adding that the testing is additive to, rather than in lieu of, clinical trials.
Testing on bioprinted skin or other miniature organs also can more readily determine which drugs that work in animals like rats might not perform well in people.
“The 3D models can circumvent animal testing and make the pathway stronger from the lab to the clinic,” Gaharwar said. That has importance for consumer goods as well as pharmaceuticals; since 2013, the European Union, for example, has prohibited cosmetics companies from testing products on animals.
The foundation for a printed organ is known as a scaffold, made of biodegradable materials. To provide nutrition for the organoid, microscopic channels only 50 microns in diameter — roughly half the size of a human hair — are included in the scaffold. Once completed, the “bioink,” a liquid combination of cells and hydrogel that turns into gelatin, is then printed onto the scaffold “like a layer cake,” Atala said.
Another important part of the process is constructing blood vessels as part of the printing. Pankaj Karande, an assistant professor of chemical and biological engineering at Rensselaer Polytechnic Institute, has been experimenting with skin printing since 2014 and recently had success in this step.
Using a cell known as a fibroblast, which helps with growth, along with collagen, as a scaffold, researchers at the institute printed the epidermis and dermis, the first two layers of skin. (The hypodermis is the third layer.) “It turns out the skin cells don’t mind being sheared,” Karande said, and they could ultimately survive.
But their work hit a snag: Without incorporating blood vessels, the skin eventually sloughs off. Collaborating with Jordan Pober and W. Mark Saltzman of Yale University, they eventually succeeded in constructing all three layers of human skin as well as vasculature, or blood vessels, which Karande said was essential to the skin’s surviving after it had been grafted.
The three began experimenting with integrating human endothelial cells, which line blood vessels, and human pericyte cells, which surround the endothelial cells, into the skin as it was printed. Eventually, after much trial and error, they were able to integrate the blood vessels with the skin and found that connections were formed between new and existing blood vessels.
While the work is preliminary — tested in mice — Karande said he was hopeful that the success in printing integrated skin and vasculature would set the stage for successful grafting in humans eventually.
The research, according to Karande, is painstaking and involves a lot of trial and error. “We have Plan A, which we often know won’t work, and then we go down the list. We can often write about what works in five pages but have 5,000 pages of what didn’t work,” he added.
c.2020 The New York Times Company